GlassScriptPhysician profile
Moin A Ranginwala
NPI 1134166317
$16,297.61
in general payments reported to CMS, 2019-2025
37 companies · $2,494 in 2025
The $2,494 reported for 2025 was more than what 80% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,051 · 2020: $754 · 2021: $1,798 · 2022: $1,354 · 2023: $495 · 2024: $1,351 · 2025: $2,494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,053 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,053.03 |
| Education | $287.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $4,595.35 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $2,832.90 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Sunovion Pharmaceuticals INC. | $1,975.64 | 2019-2020 | |
| Genzyme Corporation | $968.36 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $821.70 | 2019-2025 | |
| Glaxosmithkline, LLC. | $709.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Actelion Pharmaceuticals US, INC. | $654.07 | 2020-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $601.42 | 2019-2025 | Ofev, Jascayd |
| Amgen INC. | $589.79 | 2019-2025 | Tavneos, Tezspire, Uplizna |
| Regeneron Healthcare Solutions, INC. | $466.60 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $280.85 | 2024-2025 | Acthar |
| Grifols USA, LLC | $168.55 | 2019-2025 | Prolastin-C Liquid |
| Philips North America LLC | $160.67 | 2019-2023 | |
| Abbvie INC. | $149.05 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $122.91 | 2022-2025 | Glassia |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $109.14 | 2019-2023 | |
| Avadel Cns Pharmaceuticals, LLC | $104.72 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $96.69 | 2023-2025 | Sunosi |
| Insmed, INC. | $93.63 | 2025 | Brinsupri, Arikayce |
| Novartis Pharmaceuticals Corporation | $84.87 | 2019-2020 | |
| Ethicon INC. | $81.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $76.99 | 2022 | |
| United Therapeutics Corporation | $72.51 | 2022-2024 | Tyvaso |
| Vifor Pharma, INC. | $63.54 | 2020 | |
| Pulmonx Corporation | $63.17 | 2021 | |
| Baxter Healthcare | $57.95 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $49.58 | 2024-2025 | Smartvest |
| Alnylam Pharmaceuticals INC. | $40.95 | 2021 | |
| Harmony Biosciences LLC | $38.38 | 2025 | |
| Viatris Specialty LLC | $30.08 | 2025 | Yupelri |
| Lilly USA, LLC | $26.41 | 2025 | Zepbound |
| Genentech USA, INC. | $25.87 | 2019 | |
| La Jolla Pharmaceutical Company | $24.92 | 2025 | Giapreza |
| Verona Pharma, INC. | $18.97 | 2025 | Ohtuvayre |
| Circassia INC. | $15.69 | 2020 | |
| Boston Scientific Corporation | $13.03 | 2022 | |
| Advanced Respiratory, INC | $12.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moin Ranginwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.